Rezolute, Inc. (NASDAQ:RZLT – Get Free Report)’s stock price crossed below its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $3.94 and traded as low as $3.86. Rezolute shares last traded at $3.92, with a volume of 2,474,500 shares traded.
Wall Street Analyst Weigh In
Several research firms recently commented on RZLT. Citigroup reiterated a “market outperform” rating on shares of Rezolute in a research report on Thursday, October 15th. Zacks Research upgraded shares of Rezolute from a “strong sell” rating to a “hold” rating in a report on Wednesday. Lake Street Capital upped their price objective on Rezolute from $9.00 to $12.00 and gave the stock a “buy” rating in a report on Tuesday, October 6th. HC Wainwright lifted their price objective on shares of Rezolute from $5.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, September 25th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rezolute in a report on Thursday, October 15th. Twelve investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $11.67.
Check Out Our Latest Research Report on RZLT
Rezolute Price Performance
Rezolute (NASDAQ:RZLT – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.01. Research analysts expect that Rezolute, Inc. will post -0.66 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Rezolute
Several large investors have recently made changes to their positions in RZLT. Auxano Advisors LLC bought a new stake in Rezolute during the 2nd quarter valued at $52,000. Sequoia Financial Advisors LLC purchased a new position in shares of Rezolute during the second quarter valued at approximately $75,000. WINTON GROUP Ltd purchased a new position in shares of Rezolute during the second quarter valued at about $88,000. Hsbc Holdings PLC grew its position in shares of Rezolute by 189.4% in the 1st quarter. Hsbc Holdings PLC now owns 36,939 shares of the company’s stock worth $113,000 after buying an additional 24,177 shares during the period. Finally, American Century Companies Inc. lifted its stake in shares of Rezolute by 33.3% in the third quarter. American Century Companies Inc. now owns 33,330 shares of the company’s stock worth $138,000 after buying an additional 8,333 shares in the last quarter. 82.97% of the stock is owned by hedge funds and other institutional investors.
About Rezolute
Rezolute, Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California. It develops treatments for rare diseases, with a focus on conditions that cause dangerously low blood sugar. The company’s lead drug candidate, ersodetug (formerly RZ358), is an investigational monoclonal antibody designed to modulate insulin-receptor signaling. Rezolute is studying it for congenital hyperinsulinism, a rare disorder in which the body produces too much insulin, and other forms of severe hypoglycemia.
Recommended Stories
- Five stocks we like better than Rezolute
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Rezolute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rezolute and related companies with MarketBeat.com's FREE daily email newsletter.
